Calidi Biotherapeutics, Inc., a San Diego, CA-based clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, raised a Series A funding round of undisclosed amount.
Backers included Korean firms Won & Partners and Greentable Co., Ltd.
The company intends to use the funds to advance manufacturing in preparation for its pre-IND and IND filings.
Led by Allan Camaisa, CEO, Calidi Biotherapeutics is a clinical‐stage immuno-oncology company advancing advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Supernova 1 (SNV1c) is a tumor-selective vaccinia virus combined with allogeneic adipose-derived mesenchymal stem cells (AD-MSC).
In addition, the team is developing a universal cell delivery system to house, protect, and potentiate any oncolytic viruses currently in development which can potentially enhance efficacy and improve patient safety.